Justin Riley Lam

Thomas Jefferson University
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (11)

Year:

2026

Year:

2026

Year:

2025

Emerging evidence suggests a significant association between monocytes and the pathophysiology and prognosis of idiopathic pulmonary fibrosis (IPF). This review aims to systematically evaluate current knowledge regarding blood monocyte counts and their relationship with the etiology, progression, and prognosis of IPF. We conducted a systematic search in the PubMed database for articles published through 17 February 2025, using the MeSH terms “lung diseases, interstitial” and “monocytes,” which yielded 314 results. After filtering for full-text articles in English (n = 242), we included only studies focusing on blood monocyte counts with clinical implications in IPF. Articles relating to other cell types or non-IPF lung diseases were excluded. Our systematic search identified 12 relevant articles. Monocytes play an essential role in regulating inflammatory responses and resolution across multiple diseases, with established but incompletely understood contributions to lung fibrosis development in IPF. Correlations have been demonstrated between elevated blood monocyte counts and the following: (1) the presence and progression of interstitial lung abnormalities, (2) the progression from an indeterminate usual interstitial pneumonia (UIP) pattern on CT scans to definitive IPF, and (3) worse lung function parameters, an increased risk of acute exacerbations, and reduced overall survival in IPF patients. Monocytes serve as critical orchestrators throughout IPF’s natural history—from early interstitial changes to disease progression and acute exacerbations. Targeting monocyte recruitment pathways and reprogramming their differentiation represents a promising therapeutic approach, while circulating monocyte counts offer potential as accessible biomarkers for disease progression and treatment response. Future research should characterize stage-specific monocyte phenotypes to enable precision-targeted interventions.

Year:

2025

Vancomycin, a bacterial cell wall inhibitor, can cause nephrotoxicity, typically presenting as acute tubular necrosis (ATN) but, in rare cases, can lead to acute interstitial nephritis (AIN). Risk factors include high doses, prolonged use, other nephrotoxic drugs and pre-existing kidney impairment. This case describes a man in his 70s with multiple comorbidities who developed AIN after 9 days of vancomycin therapy for a methicillin-resistant Staphylococcus aureus infection from infective endocarditis. His serum creatinine rose from 1.2 to 5.5 mg/dL, correlating with a supratherapeutic vancomycin level (40 mcg/mL). Despite stopping vancomycin, his renal function continued to worsen, leading to a diagnosis of AIN confirmed by renal biopsy. Despite high-dose corticosteroids, haemodialysis was required to stabilise renal function, emphasising the importance of early monitoring of vancomycin levels to mitigate nephrotoxicity risks.

Year:

2025

Background: Osteoporosis is common in dialysis patients, yet treatment options are limited due to safety concerns in advanced kidney disease. Denosumab, with non-renal clearance, has been increasingly used, but its cardiovascular safety remains uncertain. Methods: We conducted a retrospective cohort study using the TriNetX Global Collaborative Network, encompassing data from 139 health care organizations. Adults older than or equal to 50 years with osteoporosis and end-stage renal disease on dialysis treated with either denosumab or oral bisphosphonates were included. Propensity score matching (1:1) balanced demographics, comorbidities, medications, and laboratory variables. The primary outcome was major adverse cardiovascular events (MACE: myocardial infarction, stroke, and heart failure). Secondary outcomes included hypocalcemia, fractures, and all-cause mortality. Cox proportional hazards models estimated hazard ratios (HRs). Results: After matching, 2112 patients (1056 per group) were analyzed (mean age: 73.9 y, 63.1% female). Denosumab was associated with increased risk of MACE (32.3% vs. 24.1%; HR: 1.690, 95% CI: 1.301-2.194; p <0.001), acute myocardial infarction, heart failure, and hypocalcemia (HR: 2.247, 95% CI: 1.650-3.061; p <0.001). Fracture incidence and all-cause mortality were not significantly different between groups. Sensitivity analyses and subgroup evaluations confirmed the robustness of these findings. Conclusions: In dialysis-dependent patients with osteoporosis, denosumab may be associated with increased cardiovascular and electrolyte-related risks compared with bisphosphonates, without clear evidence of superior fracture protection. These findings highlight the need for careful risk-benefit assessment when prescribing denosumab and underscore the importance of future prospective studies to clarify its safety and efficacy in this high-risk population.

Year:

2025

Background Cardiac resynchronization therapy (CRT) has demonstrated survival and symptom benefits in patients with heart failure with reduced ejection fraction (HFrEF). However, the comparative effectiveness of CRT with a defibrillator (CRT-D) versus pacemaker-only (CRT-P) remains uncertain in octogenarians, who are underrepresented in clinical trials. Objective To assess long-term mortality and hospitalization outcomes associated with CRT-D versus CRT-P in octogenarians with HFrEF and left bundle branch block (LBBB), using real-world propensity-matched data. Methods We identified 1,240 patients aged ≥80 years with HFrEF (LVEF ≤35%) and LBBB who underwent device implantation. After 1:1 propensity score matching across 65 clinical variables, 772 patients (386 CRT-D, 386 CRT-P) were included in the primary analysis. The primary endpoint was all-cause mortality over 3 years. Secondary endpoints included timepoint-specific mortality and all-cause hospitalization burden. Prespecified subgroup analyses were performed by ejection fraction (EF ≤25%, 26–35%) and by sex within each CRT modality. Results Three-year mortality did not differ significantly between CRT-D and CRT-P (37.2% vs 39.1%; HR 1.026, 95% CI 0.814–1.293; p = 0.829). Mortality at 30 days, 90 days, and 1 year was numerically lower in CRT-D but not statistically significant. CRT-D recipients experienced fewer hospitalizations (mean 4.05 vs 5.36; p = 0.032). In EF-stratified subgroups, mortality was modestly lower with CRT-D (risk difference –3.8% in EF ≤25%; –2.1% in EF 26–35%), though not significant. Among CRT-D recipients, females had lower mortality than males (20.0% vs 29.5%; HR 0.637, 95% CI 0.353–1.149). Conclusions In this real-world cohort of octogenarians with HFrEF, CRT-D did not improve survival over CRT-P but was associated with reduced hospitalization burden. These findings highlight the importance of phenotype-guided device selection, informed by arrhythmic risk, comorbid burden, and patient-centered goals of care.

Year:

2025

Background Multiple sclerosis (MS) is a chronic immune‐mediated disorder characterized by the degradation of the myelin sheath in the central nervous system. Research indicates that individuals with MS exhibit a higher susceptibility to stroke compared to the general population. This association is rooted in shared underlying mechanisms, specifically involving neuroinflammatory processes. Methodology We performed an extensive search on PubMed, MEDLINE, Embase, Scopus, and Google Scholar using specific terms. The search terms included variations of “multiple sclerosis,” “stroke,” “cerebrovascular disease,” “vascular risk factors,” “disease‐modifying therapies,” and “neuroinflammation.” The search was limited to articles published from January 1, 2000, up to 31 May, 2023. Results and Discussion Stroke, a global health burden characterized by significant mortality and adult disability, underscores the critical importance of understanding the link between MS and stroke. Despite a growing body of research establishing an elevated risk of stroke in MS patients, notable information gaps persist. Limited prospective multicenter studies on stroke incidence in MS patients contribute to an incomplete understanding of the precise relationship between these two conditions. Conclusion In conclusion, this review underscores the critical need for a thorough understanding of the complex relationship between MS and stroke. The identified risk factors and the influence of MS DMTs on stroke risk necessitate further investigation to inform evidence‐based preventive and therapeutic strategies. Bridging the existing information gaps through prospective multicenter studies is imperative for a comprehensive understanding of this association. The development of targeted diagnostic and therapeutic approaches for acute stroke risk in MS patients is paramount to mitigate the impact of these debilitating conditions. Ultimately, this review serves as a foundation for future efforts to enhance preventative measures and therapeutic interventions, thereby improving the overall quality of life for individuals with MS susceptible to strokes.

Year:

2024

Background Given that there is already evidence of a neural network that connects the brain and gut and that the gut microbiota actively modulates gut health, it is crucial to know which foods, supplements, and medications to use or avoid when treating any disease that causes dementia or cognitive impairment. Previous research has examined the relationships between vitamins, antibiotics, and gut microbiota and the correlations between these factors and dementia. The question arises of how these three factors interact together and if evidence suggests one element is more important than the others in the pathogenesis and development of dementia. Methods The Preferred Reporting Items for Systematic Reviews and Meta‐Analysis (PRISMA) standards were followed when conducting this review. The papers' publication dates varied from (2012−2022). Cochrane/EMBASE, PEDro, and PubMed/Medline databases were searched. The precise terms “gut microbiota,” vitamins,” antibiotics,” and “dementia” were included in the search method, along with the conjunctions “OR” and “AND.” Results Gut dysbiosis has a significant impact on cognition, brain function, and the development and progression of dementia. The two most popular probiotics used in studies linked to cognition benefits were Lactobacillus and Bifidobacterium. Numerous scales were used to evaluate cognition, but the mini‐mental state examination was the most popular, and the most prevalent impairment was Alzheimer's disease. The supplements with the most significant impact on gut microbiota were vitamin B‐12 and folic acid. Conclusion This systematic review concluded that vitamins, gut microbiota and antibiotics have a close association with the development of dementia. More research is required to establish causality and elucidate the underlying mechanisms because there is still little evidence connecting the interactions of vitamins, medications, and microbiota with dementia. The complexity of interactions between genetics, lifestyle factors, and comorbidities, as well as the heterogeneity of dementia, may make it more challenging to interpret the findings.

Year:

2024

Year:

2023

Year:

2023

Collaborators (1)

Irene J Tan

Clinical Professor of Medicine

Thomas Jefferson University

UNITED STATES
View details